James E. Ward
Impact in
- Hematology top 5%
- Multiple Myeloma Research and Treatments
- Geriatrics and Gerontology top 5%
- Sirtuins and Resveratrol in Medicine
Papers in
- Oncology 6
- Cancer Immunotherapy and Biomarkers 2
- Colorectal Cancer Treatments and Studies 2
-
- Protein Degradation and Inhibitors 2
- Co-authors
- Keith Naylor (2 shared papers)Blasé N. Polite (2 shared papers)Douglas G. McNeel (1 shared paper)Walter M. Stadler (1 shared paper)Vânia Hungria (3 shared papers)Elizabeth A. Punnoose (3 shared papers)Hans Salwender (3 shared papers)Inho Kim (3 shared papers)
- Journals
- Journal of Clinical Oncology (3 papers)Blood (2 papers)Journal of General Internal Medicine (1 paper)Clinical Cancer Research (1 paper)The Oncologist (1 paper)
- Partner nations
- United StatesSpainUnited Kingdom
In The Last Decade
James E. Ward
16 papers receiving 741 citations
James E. Ward's Hit Papers
Peers
Comparison fields: 5 of 73
- Hematology 251
- Geriatrics and Gerontology 58
- Oncology 310
- Genetics 50
- Molecular Biology 306
Countries citing papers authored by James E. Ward
This map shows the geographic impact of James E. Ward's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James E. Ward with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James E. Ward more than expected).
Fields of papers citing papers by James E. Ward
This network shows the impact of papers produced by James E. Ward. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James E. Ward. The network helps show where James E. Ward may publish in the future.
Co-authors
The 25 scholars most cited alongside James E. Ward, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial Hit paper breakdown → | 2020 | 269 |
| 2 | 2012 | 127 | |
| 3 | 2003 | 98 | |
| 4 | 2016 | 47 | |
| 5 | 2007 | 46 | |
| 6 | 2010 | 42 | |
| 7 | 2019 | 28 | |
| 8 | 2004 | 28 | |
| 9 | 2019 | 27 | |
| 10 | 2023 | 16 | |
| 11 | Colesevelam hydrochloride: Synthesis and testing of a novel polymer gel pharmaceutical. | 2000 | 15 |
| 12 | 2023 | 13 | |
| 13 | Systemic Therapy for Early-Stage Breast Cancer: What the Plastic Surgeon Should Know. | 2017 | 7 |
| 14 | 2020 | 6 | |
| 15 | 2016 | 3 | |
| 16 | 2012 | 1 |
About James E. Ward
James E. Ward is a scholar working on Oncology, Molecular Biology, Hematology, Pulmonary and Respiratory Medicine and Surgery, having authored 16 papers that have together received 773 indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (4 papers), Protein Degradation and Inhibitors (2 papers), Cancer Immunotherapy and Biomarkers (2 papers), Colorectal Cancer Treatments and Studies (2 papers), Immunotherapy and Immune Responses (2 papers), Sarcoma Diagnosis and Treatment (1 paper), Renal cell carcinoma treatment (1 paper) and Cancer Genomics and Diagnostics (1 paper). The work is most often cited by research in Hematology (251 citations), Geriatrics and Gerontology (58 citations), Oncology (310 citations), Genetics (50 citations) and Molecular Biology (306 citations). James E. Ward has collaborated with scholars based in United States, Spain and United Kingdom. Frequent co-authors include Keith Naylor, Blasé N. Polite, Douglas G. McNeel, Walter M. Stadler, Vânia Hungria, Elizabeth A. Punnoose, Hans Salwender, Inho Kim, Michèle Cavo and Javier de la Rubia. Their work appears in journals such as Journal of Clinical Oncology, Blood, Journal of General Internal Medicine, Clinical Cancer Research and The Oncologist.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.